MedTrace Logo

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

NCT03963518 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 631

Last updated 2025-10-06

Study results available
· View outcomes & findings →

Summary

Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate

Conditions

  • Cancer Treated With Immune-checkpoint Inhibitors

Interventions

DRUG

nivolumab monotherapy

nivolumab monotherapy

DRUG

nivolumab plus ipilimumab

nivolumab plus ipilimumab

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Institut Bergonié

    lead OTHER

Principal Investigators

  • Carine A Bellera, PhD · Institut Bergonié

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03963518 on ClinicalTrials.gov